Table 2.
Genotype frequencies of MDM4 polymorphisms between cases and controls and their associations with risk of SCCHN
| Genotypes | Case (n = 1,075) | Control (n = 1,079)a | Pb | OR (95% CI)c | ||
|---|---|---|---|---|---|---|
| No. | % | No. | % | |||
| rs11801299 | ||||||
| GG | 684 | 63.6 | 665 | 61.6 | 0.557 | 1.00 |
| AG | 351 | 32.7 | 376 | 34.9 | 0.90 (0.74–1.08) | |
| AA | 40 | 3.7 | 38 | 3.5 | 0.95 (0.59–1.54) | |
| AG+AA | 391 | 36.4 | 414 | 38.4 | 0.338 | 0.90 (0.75–1.08) |
| A allele | 0.200 | 0.209 | 0.465 | |||
| rs1380576 | ||||||
| CC | 487 | 45.3 | 518 | 48.0 | 0.453 | 1.00 |
| CG | 477 | 44.4 | 455 | 42.2 | 1.15 (0.96–1.39) | |
| GG | 111 | 10.3 | 106 | 9.8 | 1.17 (0.87–1.60) | |
| CG+GG | 588 | 54.7 | 561 | 52.0 | 0.208 | 1.15 (0.97–1.37) |
| G allele | 0.325 | 0.309 | 0.258 | |||
| rs10900598 | ||||||
| GG | 307 | 28.6 | 296 | 27.4 | 0.827 | 1.00 |
| GT | 545 | 50.7 | 552 | 51.2 | 0.95 (0.77–1.17) | |
| TT | 223 | 20.7 | 231 | 21.4 | 0.91 (0.70–1.17) | |
| GT+TT | 768 | 71.4 | 783 | 72.6 | 0.561 | 0.94 (0.77–1.14) |
| T allele | 0.461 | 0.470 | 0.556 | |||
| No. of combined risk genotypesd | ||||||
| 0 | 206 | 19.2 | 228 | 21.1 | 0.255 | 1.00 |
| 1–3 | 869 | 80.8 | 851 | 78.9 | 1.16 (0.93–1.45) | |
a
The observed genotype frequency among control subjects was in agreement with the Hardy-Weinberg equilibrium (Chi-square = 2.98, P = 0.084 for rs11801299, Chi-square = 0.136, P = 0.712 for rs1380576, and Chi-square = 0.713, P = 0.398 for rs10900598).
b
Two-side Chi-square test for either genotype distribution or allele frequency between cases and controls.
c
Adjusted for age, sex, smoking status, and alcohol use in a logistic regression model.
d
MDM4 rs11801299GG, rs1380576CG+GG, and rs10900598GG were considered as risk genotypes.